Literature DB >> 12046028

Antiendomysial antibodies in Berger's disease.

Alessandro Pierucci1, Claudia Fofi, Benedetta Bartoli, Bianca Maria Simonetti, Gabriella Pecci, Luigi Sabbatella, Marco Di Tola, Rosita Greco, Maria Cristina Anania, Antonio Picarelli.   

Abstract

The finding of increased levels of immunoglobulin A (IgA) against food antigens in patients with IgA nephropathy prompted the hypothesis of an association between IgA nephropathy and celiac disease (CD). Attention was initially directed to antigliadin antibodies, then to IgA antiendomysial antibodies (IgA-EMA). IgG1-EMA have been found in patients with CD with IgA-EMA-negative results. The presence of IgA- and IgG1-EMA was investigated in 36 patients with IgA nephropathy, 15 patients with other primary glomerulonephritis, and 15 patients with lupus nephritis. IgA-EMA and IgG1-EMA were detected by indirect immunofluorescence analysis. At the time of renal biopsy, the following factors were evaluated: history of macroscopic hematuria, serum creatinine level, urinalysis, 24-hour proteinuria, blood pressure, and histological classification of IgA nephropathy. Sixteen of 36 patients with IgA nephropathy (44.4%) showed EMA positivity. Among patients with positive EMA, 12 patients (75%) were IgG1-EMA positive, 2 patients (12.5%) were IgA-EMA positive, and 2 patients (12.5%) were positive for both isotypes. No significant differences were observed between the two groups (EMA positive versus EMA negative) concerning age, serum creatinine level, macroscopic hematuria, blood pressure, 24-hour proteinuria, or degree of renal histological involvement. IgA- and IgG1-EMA were not detected in patients with other primary nephropathies or lupus nephritis. These results, based on the finding of IgG1-EMA, suggest a common pathogenetic pathway for CD and IgA nephropathy. On this basis, the presence of IgG1-EMA and/or IgA-EMA should be investigated in patients with IgA nephropathy. Furthermore, the role of a gluten-free diet in the natural history of IgA nephropathy, at least in EMA-positive patients, needs to be ascertained. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12046028     DOI: 10.1053/ajkd.2002.33387

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Dysfunctions of the Iga system: a common link between intestinal and renal diseases.

Authors:  Christina Papista; Laureline Berthelot; Renato C Monteiro
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

Review 2.  The mucosa-kidney axis in IgA nephropathy.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2015-12-30       Impact factor: 28.314

3.  Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.

Authors:  Christina Papista; Sebastian Lechner; Sanae Ben Mkaddem; Marie-Bénédicte LeStang; Lilia Abbad; Julie Bex-Coudrat; Evangéline Pillebout; Jonathan M Chemouny; Mathieu Jablonski; Martin Flamant; Eric Daugas; François Vrtovsnik; Minas Yiangou; Laureline Berthelot; Renato C Monteiro
Journal:  Kidney Int       Date:  2015-03-25       Impact factor: 10.612

Review 4.  Role of IgA receptors in the pathogenesis of IgA nephropathy.

Authors:  Sebastian M Lechner; Christina Papista; Jonathan M Chemouny; Laureline Berthelot; Renato C Monteiro
Journal:  J Nephrol       Date:  2015-11-14       Impact factor: 3.902

5.  A case report: a patient with IgA nephropathy and coeliac disease. Complete clinical remission following gluten-free diet.

Authors:  Niina Koivuviita; Risto Tertti; Maija Heiro; Kaj Metsärinne
Journal:  NDT Plus       Date:  2009-01-16

6.  Lack of serologic evidence to link IgA nephropathy with celiac disease or immune reactivity to gluten.

Authors:  Sina Moeller; Pietro A Canetta; Annette K Taylor; Carolina Arguelles-Grande; Holly Snyder; Peter H Green; Krzysztof Kiryluk; Armin Alaedini
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.